Clinical trial NCT01559961: Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome
Official title: A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Interstitial Cystitis
Keywords: bladder
cystitis
frequency
nocturia
pain
urgency
Lead sponsor: Trillium Therapeutics Inc.
Sponsor class: INDUSTRY
First posted: 2012-03-21
Enrollment: 28
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and pharmacokinetics of TTI-1612 in women with interstitial cystitis/bladder pain syndrome.

Detailed description: Single doses of TTI-1612, at seven escalating dose levels, will be administered intravesically to women with IC/BPS. Drug will be retained in the bladder for 30 minutes.

TTI-1612 pharmacokinetics will be studied through the collection of blood samples at various time points, from 5 minutes to 8 hours post administration on dosing day, then at 24 and 48 hours post dosing. Serum will be isolated for subsequent analysis and determination of the following parameters: maximum serum concentration (Cmax), time of maximum observed concentration (Tmax), area under the curve to the final time with a concentration above the limit of quantification (AUC 0-t) and to infinity (AUC 0-∞), elimination half-life (t½), clearance (CL) and volume of distribution (Vz).

TTI-1612 safety will be determined through monitoring of the subjects' vital signs, ECGs, clinical laboratory evaluations, adverse events (if any) and physical examinations.

Eligibility criteria: Inclusion Criteria:

* Subject is female, 18 to 65 years old, inclusive.
* Subject has read and signed an ICF.
* Subject has BMI of 18 to 32kg/sq.m., inclusive.
* Subject has been diagnosed with IC/BPS, according to current AUA guidelines for IC/BPS.
* Subjects of child-bearing potential must agree: (1) to a double-barrier contraception method between screening and baseline visits, and (2) to abstain from sexual intercourse from baseline visit through to study completion (day 7 +/- 1 day).
* Subject has a negative serum pregnancy test at screening and at baseline.
* Subject is not lactating.
* Subject has documented negative antibody tests for HIV, HbSAg or HCV within 3 months prior to dosing or tests negative at screening.
* Subject tests negative for bladder cancer by cystoscopy within 6 months prior to dosing and tests negative by urine cytology at screening.
* Subject has clinical laboratory values (CBCs, comprehensive metabolic panel and urinalysis) that fall within normal ranges or are not clinically significant in the opinion of the Investigator.

Exclusion Criteria:

* Subject has a history of oncologic disease except non-melanoma skin cancer.
* Subject has any other condition that, in the opinion of the Investigator, may jeopardize the safety of the subject or may impact the validity of the study results.
* Subject, for whatever reason, has had substantial changes in eating habits within 30 days prior to dosing, which, in the opinion of the Investigator, may confound the planned PK evaluations or interpretation of the results of the study.
* Subject has donated blood within 30 days or plasma within 14 days prior to dosing.
* Subject has used intravesical therapy within 3 months prior to dosing.
* Subject is receiving non-stable therapy for IC/BPS (stable therapy is defined as continuous treatment for at least 6 months).
* Subject has used an investigational agent within 3 months prior to dosing.
* Subject has an ECG or vital signs at baseline that, in the opinion of the Investigator or Sponsor, is/are clinically significant.
* Subject has consumed alcohol, grapefruit, grapefruit juice or xanthine-containing beverages or foods within 48 hours prior to dosing.
* Subject has taken any known hepatic enzyme-altering drugs within 30 days prior to dosing.
* Subject has taken any known heparin-containing drugs within 30 days prior to dosing.

Primary outcomes:
measure: Safety and tolerability of TTI-1612
timeFrame: 7 days
Secondary outcomes:
measure: Pharmacokinetics
timeFrame: 5 minutes to 48 hours post dosing
Other outcomes:
Locations:
city: Brampton
country: Canada
facility: Bramalea Medical Centre
state: Ontario
city: Kitchener
country: Canada
facility: Urology Associates/Urologic Medical Research
state: Ontario
city: Oakville
country: Canada
facility: The Fe/Male Health Centres
state: Ontario
city: Toronto
country: Canada
facility: Urology & Male Fertility Clinic
state: Ontario
Study officials:
affiliation: Trillium Therapeutics Inc.
name: Penka Petrova, PhD
role: STUDY_DIRECTOR
References: